Prodrug-activating systems in suicide gene therapy

Journal of Clinical Investigation

Volumn 105, Issue 9, 2000, Pages 1161-1167

  Springer, Caroline J ^a   Niculescu Duvaz, Ion ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINOBNEZOIC ACID; 2 AMINOANTHRACENE; 4 IPOMEANOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 6 METHOXYPURINE ARABINONUCLEOSIDE; 6 METHYLPURINE 2' DEOXYRIBONUCLEOSIDE; 6 THIOXANTHINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACICLOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXIFLURIDINE; DOXORUBICIN; ENZYME; FLOXURIDINE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GANCICLOVIR TRIPHOSPHATE; IFOSFAMIDE; IRINOTECAN; N [4 (GLUTAMYLCARBONYLAMINO)BENZYLOXYCARBONYL]DOXORUBICIN; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; PRODRUG; TIOGUANINE; UNCLASSIFIED DRUG;

CANCER THERAPY; DRUG ACTIVATION; DRUG POTENCY; ENZYME ACTIVATION; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUICIDE GENE;

EID: 0034105702     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10001     Document Type: Review

References (33)

1. Marais, R., Spooner, R.A., Light, Y., Martin, J., and Springer, C.J. 1996. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56:4735-4742.
2. Bridgewater, J.A., et al. 1995. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer. 31A:2362-2370.
3. Huber, B.E., Richards, C.A., and Austin, E.A. 1995. VDEPT: an enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Advanced Drug Delivery Reviews. 17:279-292.
4. Hermiston, T. 2000. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest. 105:1169-1172.
5. Huber, B.E., Austin, E.A., Richards, C.A., Davis, S.T., and Good, S.S. 1994. Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA. 91:8302-8306.
6. Marais, R., et al. 1997. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol. 15:1373-1377.
7. Denny, W.A., and Wilson, W.R. 1998. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme prodrug therapies. J. Pharm. Pharmacol. 50:387-394.
8. Niculescu-Duvaz, I., Spooner, R., Marais, R., and Springer, C.J. 1998. Gene-directed enzyme prodrug therapy. Bioconjug. Chem. 9:4-22.
9. Encell, L.P., Landis, D.M., and Loeb, L.A. 1999. Improving enzymes for gene therapy. Nat. Biotechnol. 17:143-147.
10. Springer, C.J., and Niculescu-Duvaz, I. 1999. Patent property of prodrug involving gene therapy (1996-1999). Expert Opinion on Therapeutical Patents. 9:1381-1388.
11. Agha-Mohammadi, S., and Lotze, M.T. 2000. Immunomodulation of cancer: potential use of selectively replicating agents. J. Clin. Invest. 105:1173-1176.
12. Niculescu-Duvaz, D., et al. 1998. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. J. Med. Chem. 41:5297-5309.
13. Niculescu-Duvaz, I., et al. 1999. Self-immolative anthracycline prodrugs for suicide gene therapy. J. Med. Chem. 42:2485-2489.
14. Kievit, E., et al. 1999. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer. Cancer Res. 59:1417-1421.
15. Black, M.E., Newcomb, T.G., Wilson, H.M., and Loeb, L.A. 1996. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA. 93:3525-3529
16. Smith, G.K., et al. 1997. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J. Biol. Chem. 272:15804-15816.
17. Blanche, F., Cameron, B., Couder, M., and Crouzet. J. 1997. Rhone-Poulene Rorer. Enzymes combinations for destroying proliferative cells. Patent WO 9735024
18. Chen, L., Yu, L.J., and Waxman, D.J. 1997. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 57:4830-4837.
19. Rubsam, L.Z., Davidson, L., and Shewach, D.S. 1998. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing-cells: a novel paradigm for cell killing. Cancer Res. 58:3873-3882.
20. Waxman, D.J., and Goldstein, J.A. 1999. Trustee of Boston University. Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy. Patent WO 9905299.
21. Tiraby, M., et al. 1998. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol. Lett. 167:41-49.
22. Balzarini, G., et al. 1998. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Ther. 5:419-426.
23. Touraine, R.L., Ishii-Morita, H., Ramsey, W.J., and Blaese, R.M. 1998. The bystander effect in the HSVtk/ganciclovir system and its relation to gap junctional communication. Gene Ther. 5:1705-1711.
24. Touraine, R.L., Vahanian, N., Ramsey, W.J., and Blaese, R.M. 1998. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9:2385-2391.
25. Imaizumi, K., et al. 1998. Bystander tumoricidal effect and gap junctional communication in lung cancer cells. Am. J. Respir. Cell Mol. Biol. 18:205-212.
26. Boucher, P.D., Ruch, R.J., and Shewach, D.S. 1998. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum. Gene Ther. 9:801-814.
27. Friedlos, F., Court, S., Ford, M., Denny, W.A., and Springer, C.J. 1998. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. 5:105-112.
28. Ramesh, R., Marrogi, A.J., Munshi, A., Abboud, C.N., and Freeman, S.M. 1996. In vivo analysis of the "bystander effect": a cytokine cascade. Exp. Hematol. 24:829-838.
29. Pavlovic, J., Nawrath, M., Tu, R., Heinicke, T., and Moelling, K. 1996. Antitumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras (G12V). Gene Ther. 3:635-643.
30. Chen, S.H., et al. 1996. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 56:3758-3762.
31. Uckert, W., et al. 1998. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther. 9:855-865.
32. Heise, C.C., Williams, A., Olesch, J., and Kirn, D.H. 1999. Efficacy of a replication-competent adenovirus (ONYX-015) after intratumoral injection intratumoral spread and distribution effects. Cancer Gene Ther. 6:499-504.
33. Heise, C., and Kirn, D.H. 2000. Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest. 105:847-851.